Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Agendia launches new diagnostic test for breast cancer patients

Agendia : 05 September, 2008  (New Product)
Agendia has launched TargetPrint, a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the oestrogen receptor (ER), progesterone receptor (PR) and Human Epidermal growth factor Receptor 2 (HER2) in breast cancer tumour biopsies.
The accurate measurement of these receptors is of paramount importance in planning treatment of breast cancer patients after surgery and assists physicians and patients in making informed treatment decisions. TargetPrint runs on Agendia's new High Density Chip, which received market clearance in August 2008 from the US FDA.

'Currently available targeted therapies, such as hormone treatments, can have a huge impact on the survival and quality of life of a significant number of breast cancer patients,' said Bernhard Sixt, PhD, president and chief executive officer of Agendia. 'TargetPrint will play a key role in defining which patients are most likely to benefit from these treatments.'

'The test's results give a precise molecular read-out of prognostic parameters for breast cancer and provide physicians and patients with reliable guidance on the most suitable treatment for each individual patient,' said Richard A Bender, MD, FACP, chief medical officer of Agendia. 'In the near future, it is our plan to add information on a wider range of drug targets to TargetPrint and clinically validate these with key customers.'

Agendia will present clinical data on TargetPrint at The 2008 Breast Cancer Symposium which is co-sponsored by the American Society of Clinical Oncology (ASCO) and will be held in Washington, DC from September 5 to 7, 2008. TargetPrint is processed at Agendia's Clinical Laboratory Improvement Amendments (CLIA) certified and the College of American Pathology (CAP) accredited laboratory.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo